论文部分内容阅读
目的探讨蚓激酶联合阿司匹林治疗脑梗死的临床疗效。方法84例脑梗死患者随机分为治疗组和对照组各42例,两组在常规治疗的基础上,对照组单用阿司匹林100 mg,口服,每天1次;治疗组在对照组的基础上加用蚓激酶60 mg,口服,每天3次,连用14 d,观察疗效。结果治疗组总有效率(90.48%)明显高于对照组(66.67%)(P<0.05)。治疗组和对照组治疗后血小板聚集率及治疗组全血高切、低切粘度、血浆比粘度及全血粘度均较治疗前显著降低(P<0.05),而凝血指标两组治疗前后对比差异均无统计学意义;治疗组治疗期间出现尿隐血1例,无其他不良反应。结论蚓激酶联合阿司匹林治疗急性脑梗死疗效较好,不良反应较少。
Objective To investigate the clinical efficacy of lumbrokinase combined with aspirin in the treatment of cerebral infarction. Methods Eighty-four patients with cerebral infarction were randomly divided into treatment group (n = 42) and control group (n = 42). On the basis of conventional treatment, the two groups were given aspirin 100 mg orally once daily. In the control group, With Lumbrokinase 60 mg, orally, 3 times a day, once every 14 d, observe the effect. Results The total effective rate (90.48%) in the treatment group was significantly higher than that in the control group (66.67%) (P <0.05). After treatment, the platelet aggregation rate and the whole blood high-cut, low-cut viscosity, plasma viscosity and whole blood viscosity of the treatment group and the control group were significantly lower than those before treatment (P <0.05), while the difference of the coagulation index between the two groups before and after treatment No statistical significance; treatment group during the treatment of urinary occult blood in 1 case, no other adverse reactions. Conclusion Lumbrokinase plus aspirin is effective in treating acute cerebral infarction with less adverse reactions.